Investor Presentaiton

SNS812 Advantages SNS812 covers 99.8% variants and can inhibit virus by both prophylactic and post-exposure treatment. Name Classification SNS812 Nucleic acid/ siRNA Molnupiravir Small chemical/ Nucleoside analogs MK-4482 PAXLOVID Small chemical/ Protease inhibitor PF-07321332 + Ritonavir ΑΡΙ C6G25S Mechanism of action Cleavage viral RNA by siRNA targeting Cause accumulation of mutation in viral RNA Inhibit viral 3CL protease Route of administration Inhalation Oral Oral Coverage rates of variants 99.80% ND ND Resistant to viral mutation Relatively resistant viral mutation ND ND Potential drug-drug interactions of Pontential risk ND Mutagenic concern (1) Animal efficacy hACE2 transgenic mice (reduce 2.6 logs) Clinical reduction of severe illness ND Human lung transplant mice (reduce 4.4 logs) (3) 50% Ritonavir (2) BALB/c mice + mice adapted virus. (reduce 1.9 logs) (4) 89% 1. B-d-N4-hydroxycytidine Inhibits SARS-CoV-2 Through Lethal Mutagenesis But Is Also Mutagenic To Mammalian Cells. J Infect Dis. 2021 Aug 2;224(3):415-419 2. Caution required with use of ritonavir-boosted PF-07321332 in COVID-19 management. The Lancet 2022 Jan 1; 399(10319): 21-22 3. SARS-CoV-2 infection is effectively treated and prevented by EIDD-2801. Nature 2021; 591: 451-457. 4. An oral SARS-CoV-2 Mpro inhibitor clinical candidate for the treatment of COVID-19. Science 2021 Dec 24;374(6575):1586-1593 ONENESS | 29

View entire presentation